Clinical trials: Stage III
Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic
A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients
A Phase III, Multicenter, open-labeded study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and Ribavirin for 12 weeks of treatment in HCV Genotype I Infected Patients
- Conditions
- Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic, Cirrhosis, Treatment naïve
- Trial name
- NCT04155515
- Testing
- TG-2349, DAG181, Ribavirin
- Where
- China
- Volunteers
- 370 people
- Sponsor
- Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Cardiovascular Disease, Coronary Artery Bypass Surgery
Angiomax in Patients With HIT/HITTS Type II Undergoing CPB
The purpose of this study is to demonstrate that in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) Type II undergoing cardiac surgery on cardiopulmonary…
- Trial name
- HIT/TS (NCT00079508)
- Testing
- Angiomax (bivalirudin)
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- The Medicines Company
Urinary Tract Infection (UTI), Complicated Urinary Tract Infection
Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)
This is a Phase 3, multi-site, non-randomized, open-label study evaluating the safety and efficacy of MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) for the treatment of complicated urinary tract infection (cUTI) including…
- Conditions
- Urinary Tract Infection (UTI), Complicated Urinary Tract Infection, Pyelonephritis, Uncomplicated Pyelonephritis
- Trial name
- NCT02728089
- Testing
- MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)
- Volunteers
- 115 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus
Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)
This study will evaluate the safety and efficacy of combination treatment with grazoprevir (MK-5172) + elbasvir (MK-8742) for cirrhotic and non-cirrhotic participants with chronic Genotype 1 (GT1) hepatitis C virus (HCV)…
- Trial name
- C-SURFER (NCT02092350)
- Testing
- Grazoprevir, Elbasvir
- Volunteers
- 237 people
- Sponsor
- Merck Sharp & Dohme LLC
Open-Angle Glaucoma, Ocular Hypertension
A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to demonstrate equivalent safety and IOP-lowering effectiveness of two Travoprost/Timolol combination products in patients diagnosed with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00672997
- Testing
- Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution, Travoprost 0.004%/Timolol 0.5% ophthalmic solution
- Volunteers
- 301 people
- Sponsor
- Alcon Research
Hemophilia A
Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Severe Haemophilia A.
This study is a multicenter phase III uncontrolled open-label trial to evaluate the efficacy,safety and pharmacokinetics of SCT800 in regular prophylaxis and perioperative treatment in patients (<12 years old) with severe…
- Trial name
- NCT03947320
- Testing
- Recombinant Human Coagulation FVIII
- Volunteers
- 70 people
- Sponsor
- Sinocelltech Ltd.
Surgical Site Infection, Colon Surgery
D-PLEX 311: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection
Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to assess Efficacy and Safety of D-PLEX Administered Concomitantly with the Standard of Care (SoC), compared to a SoC treated…
- Conditions
- Surgical Site Infection, Colon Surgery, Abdominal Surgery, Post-Op Infection
- Trial name
- NCT04233424
- Testing
- D-PLEX, Standard of Care (SoC)
- Where
- 62 sites in United States, Bulgaria and 8 more
- Volunteers
- 977 people
- Sponsor
- PolyPid Ltd.
Myeloma Multiple
A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)
The aim of the study is to assess the efficacy and safety of the BCD-248 in combination with daratumumab versus the combination of daratumumab, pomalidomide, and dexamethasone in the treatment of relapsed or refractory multiple…
- Trial name
- AMMADINA (NCT07742215)
- Testing
- BCD-248 + daratumumab, Daratumumab + pomalidomide + dexamethasone
- Where
- 16 sites in Belarus, Russia
- Volunteers
- 390 people
- Sponsor
- Biocad
Acute Ischemic Stroke
Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke
This study is designed to determine the efficacy and safety of SHPL-49 intravenous infusion in acute ischemic stroke patients.
- Trial name
- SAIL (NCT07241520)
- Testing
- SHPL-49 Injection
- Where
- China
- Volunteers
- 1,096 people
- Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
Type 2 Diabetes Mellitus
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients
This study is to evaluate the efficacy and safety after concomitant administration of ASP1941 and sulfonylurea in patients with diabetes mellitus.
- Trial name
- NCT01242215
- Testing
- ipragliflozin, Sulfonylurea
- Where
- 7 sites in Japan
- Volunteers
- 243 people
- Sponsor
- Astellas Pharma Inc
COVID-19
Study to Assess the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19)
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of STI-1558 in adult subjects with mild/moderate COVID-19.
- Trial name
- NCT05716425
- Testing
- STI-1558
- Where
- 2 sites in China
- Volunteers
- 1,218 people
- Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
Pulmonary Arterial Hypertension
A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension
The purpose of this study is to evaluate the effect of macitentan on hemodynamic measures at Week 24 in pediatric populations.
- Trial name
- NCT05167825
- Testing
- Macitentan
- Where
- 11 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Janssen Pharmaceutical K.K.
Type 2 Diabetes (T2DM)
Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes
Evaluate the efficacy of GZR33 Injection and Insulin Degludec Injection (Tresiba®) in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Oral Antidiabetic Drugs.
- Trial name
- NCT07527078
- Testing
- GZR33 Injection, Insulin Degludec Injection (Tresiba®)
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Melanoma (Skin)
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
RATIONALE: Vaccines made from a person's melanoma cells may make the body build an immune response to kill tumor cells. Interferon alfa may interfere with the growth of the cancer cells.
- Trial name
- NCT00003715
- Testing
- BCG vaccine, autologous tumor cell vaccine, recombinant interferon alfa
- Where
- 17 sites in United States
- Volunteers
- 425 people
- Sponsor
- AVAX Technologies
Melanoma
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
This was a two-arm, open-label, randomized, Phase III study comparing dabrafenib (GSK2118436) and trametinib (GSK1120212) combination therapy with vemurafenib.
- Trial name
- COMBI-v (NCT01597908)
- Testing
- Dabrafenib, Vemurafenib, Trametinib
- Where
- 205 sites in United States, Argentina and 26 more
- Volunteers
- 704 people
- Sponsor
- Novartis Pharmaceuticals
Keratoconjunctivitis, Conjunctivitis
Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis
To investigate the long-term efficacy and safety of FK506 ophthalmic suspension in patients with vernal keratoconjunctivitis
- Trial name
- NCT00567918
- Testing
- FK506
- Where
- 8 sites in Japan
- Volunteers
- 52 people
- Sponsor
- Astellas Pharma Inc
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS
This study compares the safety and effectiveness of giving rivogenlecleucel (BPX-501 T cells) to patients with AML or MDS post haploidentical hematopoietic stem cell transplant compared to post-transplant cyclophosphamide.
- Trial name
- THRIVE (NCT03699475)
- Testing
- rivogenlecleucel, rimiducid, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Bellicum Pharmaceuticals
Ileus
Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus
Patients undergoing major abdominal surgery are at highest risk for developing postoperative ileus (POI), occurring in nearly all cases.
- Trial name
- NCT00388401
- Testing
- Alvimopan
- Where
- United States
- Volunteers
- 510 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Schizophrenia
A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
This multi-center, randomized, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 in participants with persistent, predominant negative symptoms of schizophrenia.
- Trial name
- NCT01192867
- Testing
- RO4917838, Antipshychotics (Standard of Care)
- Where
- 122 sites in United States, Argentina and 12 more
- Volunteers
- 629 people
- Sponsor
- Hoffmann-La Roche
Macular Edema, Retinal Vein Occlusion
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)
This was a Phase III, multicenter, randomized, double-masked, sham injection-controlled study of the efficacy and safety of intravitreal ranibizumab compared with sham injections in patients with macular edema secondary to…
- Trial name
- CRUISE (NCT00485836)
- Testing
- Ranibizumab injection 0.3 mg, Ranibizumab injection 0.5 mg
- Volunteers
- 392 people
- Sponsor
- Genentech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.